Molecular interaction study of novel indoline derivatives with EGFR-kinase domain using multiple computational analysis

References

• Acharya, R., Chacko, S., Bose, P., Lapenna, A., & Pattanayak, S. P. (2019). Structure based multitargeted molecular docking analysis of selected furanocoumarins against breast cancer. Scientific Reports, 9(1), 15743.
   Google Scholar
• Ayati, A., Moghimi, S., Salarinejad, S., Safavi, M., Pouramiri, B., & Foroumadi, A. (2020). A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorganic Chemistry, 99, 103811. https://doi.org/10.1016/j.bioorg.2020.103811
   PubMed Web of Science ®Google Scholar
• Bethune, G., Bethune, D., Ridgway, N., & Xu, Z. (2010). Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update. Journal of Thoracic Disease, 2(1), 48–51.
   PubMedGoogle Scholar
• Bommu, U. D., Konidala, K. K., Pamanji, R., & Yeguvapalli, S. (2018). Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor. Journal of Receptors and Signal Transduction, 38(1), 48–60. https://doi.org/10.1080/10799893.2018.1426603
   PubMed Web of Science ®Google Scholar
• Crunkhorn, S. (2018). Cancer: Combating resistance to EGFR inhibitors. Nature Reviews. Drug Discovery, 18(1), 18. https://doi.org/10.1038/nrd.2018.232
   Google Scholar
• Dixon, S. L., Smondyrev, A. M., Knoll, E. H., Rao, S. N., Shaw, D. E., & Friesner, R. A. (2006). PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. Journal of Computer-Aided Molecular Design, 20(10–11), 647–671. https://doi.org/10.1007/s10822-006-9087-6
   PubMed Web of Science ®Google Scholar
• Kitazaki, T., Oka, M., Nakamura, Y., Tsurutani, J., Doi, S., Yasunaga, M., Takemura, M., Yabuuchi, H., Soda, H., & Kohno, S. (2005). Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer (Amsterdam, Netherlands), 49(3), 337–343. https://doi.org/10.1016/j.lungcan.2005.03.035
   PubMed Web of Science ®Google Scholar
• Liao, Q.-H., Gao, Q.-Z., Wei, J., & Chou, K.-C. (2011). Docking and molecular dynamics study on the inhibitory activity of novel inhibitors on epidermal growth factor receptor (EGFR). Medicinal Chemistry (Shariqah (United Arab Emirates), 7(1), 24–31. https://doi.org/10.2174/157340611794072698
   PubMed Web of Science ®Google Scholar
• Liao, B. C., Lin, C. C., & Yang, J. C. H. (2017). Novel EGFR inhibitors in non-small cell lung cancer: Current status of Afatinib. Current Oncology Reports, 19(1), 4. https://doi.org/10.1007/s11912-017-0560-2
   Google Scholar
• Lyne, P. D., Lamb, M. L., & Saeh, J. C. (2006). Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. Journal of Medicinal Chemistry, 49(16), 4805–4808. https://doi.org/10.1021/jm060522a
   PubMed Web of Science ®Google Scholar
• Madhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013). Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design, 27(3), 221–234. https://doi.org/10.1007/s10822-013-9644-8
   PubMed Web of Science ®Google Scholar
• Maennling, A. E., Tur, M. K., Niebert, M., Klockenbring, T., Zeppernick, F., Gattenlöhner, S., Meinhold-Heerlein, I., & Hussain, A. F. (2019). Molecular targeting therapy against EGFR family in breast cancer: Progress and future potentials. Cancers, 11(12), 1826. https://doi.org/10.3390/cancers11121826
   PubMed Web of Science ®Google Scholar
• Mahmoud, S., Samaha, D., Mohamed, M. S., Abou Taleb, N. A., Elsawy, M. A., Nagamatsu, T., & Ali, H. I. (2020). Design, synthesis, antitumor activity and molecular docking study of novel 5-deazaalloxazine analogs. Molecules, 25(11), 2518. https://doi.org/10.3390/molecules25112518
   PubMed Web of Science ®Google Scholar
• Martelli, A. M. (2010). The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histology and Histopathology, 25(5), 669–680.
   PubMed Web of Science ®Google Scholar
• Palanivel, S., Murugesan, A., Subramanian, K., Yli-Harja, O., & Kandhavelu, M. (2020a). Antiproliferative and apoptotic effects of indole derivative, N-(2-hydroxy-5-nitrophenyl (4'-methylphenyl) methyl) indoline in breast cancer cells. European Journal of Pharmacology, 881, 173195. https://doi.org/10.1016/j.ejphar.2020.173195
   PubMed Web of Science ®Google Scholar
• Palanivel, S., Murugesan, A., Yli-Harja, O., & Kandhavelu, M. (2020b). Anticancer activity of THMPP: Downregulation of PI3K/ S6K1 in breast cancer cell line. Saudi Pharmaceutical Journal, 28(4), 495–503. https://doi.org/10.1016/j.jsps.2020.02.015
   PubMed Web of Science ®Google Scholar
• Palanivel, S., Yli-Harja, O., & Kandhavelu, M. (2020c). Alkylamino phenol derivative induces apoptosis by inhibiting EGFR signaling pathway in breast cancer cells. Anti-Cancer Agents in Medicinal Chemistry, 20(7), 809–819. https://doi.org/10.2174/1871520620666200213101407
   PubMed Web of Science ®Google Scholar
• Pao, W., & Girard, N. (2010). Clinical applications of kinase inhibitors in solid tumors. In Handbook of Cell Signaling, 2/e (vol. 2, pp. 615–631). Elsevier Inc.
   Google Scholar
• Schrödinger, L. (2019a). Desmond molecular dynamics system, D. E. Shaw Research, New York, Maestro-desmond interoperability tools, Schrödinger, New York, NY, 2020.
   Google Scholar
• Schrödinger, L. (2019b). LigPrep, Schrödinger. LLC.
   Google Scholar
• Schrödinger, L. (2019c). QikProp, Schrödinger. LLC.
   Google Scholar
• Schrödinger, L. L. C. (2015). The {PyMOL} molecular graphics system, Version∼1.8.
   Google Scholar
• Shahare, H. V., & Talele, G. S. (2020). Designing of benzothiazole derivatives as promising EGFR tyrosine kinase inhibitors: A pharmacoinformatics study. Journal of Biomolecular Structure & Dynamics, 38(5), 1365–1374. https://doi.org/10.1080/07391102.2019.1604264
   PubMed Web of Science ®Google Scholar
• Shaik, N. A., Al-Kreathy, H. M., Ajabnoor, G. M., Verma, P. K., & Banaganapalli, B. (2019). Molecular designing, virtual screening and docking study of novel curcumin analogue as mutation (S769L and K846R) selective inhibitor for EGFR. Saudi Journal of Biological Sciences, 26(3), 439–448. https://doi.org/10.1016/j.sjbs.2018.05.026
   PubMed Web of Science ®Google Scholar
• Sigismund, S., Avanzato, D., & Lanzetti, L. (2018). Emerging functions of the EGFR in cancer. Molecular Oncology, 12(1), 3–20. https://doi.org/10.1002/1878-0261.12155
   PubMed Web of Science ®Google Scholar
• Singh, D., Kumar Attri, B., Kaur Gill, R., & Bariwal, J. (2016). Review on EGFR inhibitors: Critical updates. Mini Reviews in Medicinal Chemistry, 16(14), 1134–1166. https://doi.org/10.2174/1389557516666160321114917
   PubMed Web of Science ®Google Scholar
• Tripathi, S. K., Muttineni, R., & Singh, S. K. (2013). Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. Journal of Theoretical Biology, 334, 87–100. https://doi.org/10.1016/j.jtbi.2013.05.014
   PubMed Web of Science ®Google Scholar
• Verma, G., Khan, M. F., Akhtar, W., Alam, M. M., Akhter, M., Alam, O., Hasan, S. M., & Shaquiquzzaman, M. (2019). Pharmacophore modeling, 3D-QSAR, docking and ADME prediction of quinazoline based EGFR inhibitors. Arabian Journal of Chemistry, 12(8), 4815–4839. https://doi.org/10.1016/j.arabjc.2016.09.019
   Web of Science ®Google Scholar
• Xu, X., Qiu, G., Ji, L., Ma, R., Dang, Z., Jia, R., & Zhao, B. (2019). Research and development of anticancer agents under the guidance of biomarkers. Cancer Translational Medicine, 5(1), 17. https://doi.org/10.4103/ctm.ctm_2_19
   Google Scholar
• Yan, L., Rosen, N., & Arteaga, C. (2011). Targeted cancer therapies. Chinese Journal of Cancer, 30(1), 1–4. https://doi.org/10.5732/cjc.010.10553
   PubMedGoogle Scholar